GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rapid Micro Biosystems Inc (NAS:RPID) » Definitions » Intrinsic Value: Projected FCF

Rapid Micro Biosystems (Rapid Micro Biosystems) Intrinsic Value: Projected FCF : $0.00 (As of May. 16, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rapid Micro Biosystems Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-16), Rapid Micro Biosystems's Intrinsic Value: Projected FCF is $0.00. The stock price of Rapid Micro Biosystems is $0.8099. Therefore, Rapid Micro Biosystems's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Rapid Micro Biosystems's Intrinsic Value: Projected FCF or its related term are showing as below:

RPID's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.78
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Rapid Micro Biosystems Intrinsic Value: Projected FCF Historical Data

The historical data trend for Rapid Micro Biosystems's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Micro Biosystems Intrinsic Value: Projected FCF Chart

Rapid Micro Biosystems Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

Rapid Micro Biosystems Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Rapid Micro Biosystems's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, Rapid Micro Biosystems's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Micro Biosystems's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Rapid Micro Biosystems's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Rapid Micro Biosystems's Price-to-Projected-FCF falls into.



Rapid Micro Biosystems Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Rapid Micro Biosystems  (NAS:RPID) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Rapid Micro Biosystems's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.8099/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rapid Micro Biosystems Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Rapid Micro Biosystems's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Micro Biosystems (Rapid Micro Biosystems) Business Description

Traded in Other Exchanges
N/A
Address
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA, USA, 01854
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Executives
Sean M Wirtjes officer: Chief Financial Officer C/O VARIAN, INC., 3120 HANSEN WAY, M/S D-083, PALO ALTO CA 94304-1030
Spignesi Robert G. Jr. director, officer: President and CEO C/O RAPID MICRO BIOSYSTEMS, INC., 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Kirk Malloy director 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kennedy Lewis Capital Partners Master Fund Ii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Klm Gp Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Capital Partners Master Fund Iii Lp 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Gp Iii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Holdings Ii Llc 10 percent owner 111 WEST 33RD STREET, SUITE 1910, NEW YORK NY 10120
Kennedy Lewis Investment Management Llc 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Kennedy Lewis Management Lp 10 percent owner 225 LIBERTY STREET, SUITE 4210, NEW YORK NY 10281
David Chene 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Darren Richman 10 percent owner 80 BROAD STREET, 22ND FLOOR, NEW YORK NY 10004
Inese Lowenstein director C/O RAPID MICRO BIOSYSTEMS INC, 1001 PAWTUCKET BOULEVARD WEST, SUITE 280, LOWELL MA 01854
Richard A Keys officer: CHIEF COMMERCIAL OFFICER C/O RAPID MICRO BIOSYSTEMS INC, 1001 PAWTUCKET BOULEVARD, SUITE 280, LOWELL MA 01854